A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). (Q33753874)

29 July 2017

title

A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). (English)

1 reference

29 July 2017

main subject

phase III clinical trial

0 references

1 reference

3

Anthony E Lang

1 reference

29 July 2017

4

Robert A Hauser

1 reference

29 July 2017

11

Diony Young

1 reference

29 July 2017

12

Tanya Simuni

1 reference

29 July 2017

9

Ira Shoulson

1 reference

29 July 2017

2

David Oakes

1 reference

29 July 2017

Kevin M Biglan

1

1 reference

29 July 2017

Karen Hodgeman

5

1 reference

29 July 2017

Brittany Greco

6

1 reference

29 July 2017

Jillian Lowell

7

1 reference

29 July 2017

Rebecca Rockhill

8

1 reference

29 July 2017

Charles Venuto

10

1 reference

29 July 2017

Parkinson Study Group STEADY‐PD III Investigators

13

1 reference

29 July 2017

publication date

9 May 2017

1 reference

Annals of clinical and translational neurology

29 July 2017

published in

1 reference

29 July 2017

volume

4

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

360-368

1 reference

Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Psychosis, apathy, depression and anxiety in Parkinson's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Systematic review of levodopa dose equivalency reporting in Parkinson's disease.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Calcium channel blocker use and risk of Parkinson's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

L-type calcium channel blockers and Parkinson disease in Denmark

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Neuroprotection trials in Parkinson's disease: systematic review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

'Rejuvenation' protects neurons in mouse models of Parkinson's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Calcium channel blockers and beta-blockers in relation to Parkinson's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Epidemiology of Parkinson's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Levodopa and the progression of Parkinson's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Measuring the impact of Parkinson's disease with the Parkinson's Disease Quality of Life questionnaire.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Parkinsonism: onset, progression, and mortality

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5454402

Burden of illness in Parkinson's disease

21 June 2018

1 reference

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

21 January 2018

1 reference

Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms

21 January 2018

1 reference

Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons.

21 January 2018

1 reference

Use of antihypertensives and the risk of Parkinson disease

21 January 2018

1 reference

Use of calcium channel blockers and Parkinson's disease

21 January 2018

1 reference

Dihydropyridine calcium channel blockers and the progression of parkinsonism

21 January 2018

1 reference

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease

21 January 2018

1 reference

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group

21 January 2018

1 reference

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

What should be defined as good outcome in stroke trials; a modified Rankin score of 0-1 or 0-2?

21 January 2018

1 reference

The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease

21 January 2018

1 reference

Interpreting the results of Parkinson's disease clinical trials: Time for a change

21 January 2018

1 reference

A longitudinal program for biomarker development in Parkinson's disease: a feasibility study

21 January 2018

1 reference

Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra

21 January 2018

1 reference

Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life.

21 January 2018

1 reference

Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries

21 January 2018

1 reference

The impact of non‐motor symptoms on health‐related quality of life of patients with Parkinson's disease

21 January 2018

1 reference

Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden.

21 January 2018

1 reference

Differential contributions of cognitive and motor component processes to physical and instrumental activities of daily living in Parkinson's disease

21 January 2018

1 reference

PubMed

12 December 2020

Depression in Parkinson's disease

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

The Long-Duration Action of Levodopa May Be Due to a Postsynaptic Effect

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1002/ACN3.412

1 reference

29 July 2017

1 reference

29 July 2017

1 reference